Vitamin D3 supplementation in COVID-19 patients with cardiovascular disease and gut dysbiosis

Hipertens Riesgo Vasc. 2024 Jul-Sep;41(3):145-153. doi: 10.1016/j.hipert.2024.04.002. Epub 2024 Jun 12.

Abstract

Background: The COVID-19 pandemic has highlighted the vulnerability of particular patient groups to SARS-CoV-2 infection, including those with cardiovascular diseases, hypertension, and intestinal dysbiosis. COVID-19 affects the gut, suggesting diet and vitamin D3 supplementation may affect disease progression.

Aims: To evaluate levels of Ang II and Ang-(1-7), cytokine profile, and gut microbiota status in patients hospitalized for mild COVID-19 with a history of cardiovascular disease and treated with daily doses of vitamin D3.

Methods: We recruited 50 adult patients. We screened 50 adult patients and accessed pathophysiology study 22, randomized to daily oral doses of 10,000IU vitamin D3 (n=11) or placebo (n=11). Plasma levels of Ang II and Ang-(1-7) were determined by radioimmunoassay, TMA and TMAO were measured by liquid chromatography and interleukins (ILs) 6, 8, 10 and TNF-α by ELISA.

Results: The Ang-(1-7)/Ang II ratio, as an indirect measure of ACE2 enzymatic activity, increased in the vitamin D3 group (24±5pg/mL vs. 4.66±2pg/mL, p<0.01). Also, in the vitamin D3-treated, there was a significant decline in inflammatory ILs and an increase in protective markers, such as a substantial reduction in TMAO (5±2μmoles/dL vs. 60±10μmoles/dL, p<0.01). In addition, treated patients experienced less severity of infection, required less intensive care, had fewer days of hospitalization, and a reduced mortality rate. Additionally, improvements in markers of cardiovascular function were seen in the vitamin D3 group, including a tendency for reductions in blood pressure in hypertensive patients.

Conclusions: Vitamin D3 supplementation in patients with COVID-19 and specific conditions is associated with a more favourable prognosis, suggesting therapeutic potential in patients with comorbidities such as cardiovascular disease and gut dysbiosis.

Keywords: Angiotensin; Angiotensina; COVID-19; Disbiosis intestinal; Gut dysbiosis; Hipertensión; Hypertension; Inflammatory markers; Marcadores inflamatorios; Trimethylamine; Trimetilamina; Vitamin D3; Vitamina D3.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Angiotensin I / blood
  • Angiotensin II / blood
  • Angiotensin-Converting Enzyme 2 / metabolism
  • COVID-19 Drug Treatment
  • COVID-19* / complications
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Cholecalciferol* / administration & dosage
  • Cytokines / blood
  • Dietary Supplements*
  • Double-Blind Method
  • Dysbiosis*
  • Female
  • Gastrointestinal Microbiome*
  • Humans
  • Male
  • Methylamines / blood
  • Middle Aged
  • Peptide Fragments* / blood
  • SARS-CoV-2
  • Vitamins / administration & dosage

Substances

  • Cholecalciferol
  • Peptide Fragments
  • Angiotensin I
  • angiotensin I (1-7)
  • Angiotensin II
  • trimethyloxamine
  • Vitamins
  • Methylamines
  • Cytokines
  • Angiotensin-Converting Enzyme 2
  • ACE2 protein, human